You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾美疫苗(06660.HK):四價結合流腦疫苗II期臨牀試驗啟動
格隆匯 03-04 07:56

格隆匯3月4日丨艾美疫苗(06660.HK)發佈公吿,2024年3月2日,集團四價結合流腦疫苗II期隨機、盲法、同類疫苗平行對照臨牀試驗,以雲南省疾病預防控制中心作為負責機構,保山市隆陽區疾病預防控制中心和大理州巍山彝族回族自治縣疾病預防控制中心作為研究現場,正式啟動II期臨牀試驗。

流行性腦脊髓膜炎(簡稱流腦)是一種細菌性疫苗可預防的疾病,由奈瑟氏腦膜炎球菌引起的以腦膜炎和敗血症為臨牀表現的急性傳染病,該病分佈廣、發病急、進展快、傳染性強、隱性感染率高、病死率較高,危害嚴重。在世界衞生組織可用疫苗預防的疾病分級中,流腦系列產品處於高度優先級別。集團四價結合流腦疫苗,可預防A羣、C羣、Y羣和W135羣腦膜炎球菌引起的流行性腦脊髓膜炎和其他侵襲性疾病。

目前,集團已完成四價結合流腦疫苗生產車間的建設,產品上市後將有廣闊的市場前景。2023年腦膜炎結合疫苗產品全球銷售額約14.18億美元。未來公司的兩款流腦疫苗將同時為我國控制流腦疾病助力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account